Overview of Clinical Data and Treatment Selection in Later-Line HER2+ Metastatic Breast Cancer

Opinion
Video

Panelists discuss how clinical data and treatment selection in later-line HER2+ metastatic breast cancer are informed by the latest therapeutic advancements, including targeted therapies like trastuzumab deruxtecan (T-DXd) and tucatinib, to optimize patient outcomes and manage progression.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
4 experts in this video
4 experts in this video
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
2 experts are featured in this series.
Related Content